Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gadofosveset
Drug ID BADD_D00987
Description Gadofosveset trisodium is an intravenous contrast agent used with magnetic resonance angiography(MRA), which is a non-invasive way of imaging blood vessels. The agent allows for the vascular system to be imaged more clearly by the MRA. In this way, gadofosveset trisodium is used to help diagnose certain disorders of the heart and blood vessels.
Indications and Usage Gadofosveset trisodium is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.
Marketing Status approved
ATC Code V08CA11
DrugBank ID DB06705
KEGG ID D08005
MeSH ID C109932
PubChem ID 46174086
TTD Drug ID D0H0WK
NDC Product Code Not Available
UNII E65RW73PHS
Synonyms gadofosveset trisodium | gadofosveset | MS 325 | MS-325 | Vasovist
Chemical Information
Molecular Formula C33H41GdN3O14P
CAS Registry Number 193901-90-5
SMILES [H+].[H+].[H+].C1CC(CCC1OP(=O)([O-])OCC(CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-]) N(CC(=O)[O-])CC(=O)[O-])(C2=CC=CC=C2)C3=CC=CC=C3.[Gd+3]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Phlebitis24.12.03.004; 12.02.01.002--
Pollakiuria20.02.02.007--
Pruritus23.03.12.001--
Pruritus genital23.03.12.008; 21.10.01.002--Not Available
Rash23.03.13.001--Not Available
Renal pain20.02.03.003--Not Available
Respiratory depression17.02.05.047; 22.02.01.010--Not Available
Retching07.01.07.002--Not Available
Salivary hypersecretion07.06.01.009--Not Available
Shock24.06.02.002--Not Available
Skin disorder23.03.03.007--Not Available
Swelling face23.04.01.018; 08.01.03.100; 10.01.05.018--Not Available
Tachycardia02.03.02.007--Not Available
Tremor17.01.06.002--
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Vertigo04.04.01.003; 17.02.12.002--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Muscle tightness15.05.03.007--Not Available
Injection site coldness12.07.03.023; 08.02.03.023--Not Available
Sticky skin23.03.03.019--Not Available
Cardiac flutter02.03.02.012--Not Available
Genital burning sensation21.10.01.005--Not Available
Hypoaesthesia oral17.02.06.021; 07.05.05.003--Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages